XML 45 R33.htm IDEA: XBRL DOCUMENT v3.25.2
Collaborative Research and Development Agreements - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Jan. 31, 2025
Nov. 24, 2023
Oct. 23, 2020
Mar. 31, 2014
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Disaggregation of Revenue [Line Items]                
Collaboration revenue         $ 22,263,000 $ 10,971,000 $ 50,034,000 $ 18,150,000
Other income (expense), net         3,531,000 0 5,433,000 (2,000)
GSK | GlaxoSmithKline Collaboration | PD-1 (Jemperli/Dostarlimab)                
Disaggregation of Revenue [Line Items]                
Agreement term following first commercial sale or expiration of the last to expire patent (in years)     12 years          
GSK | GlaxoSmithKline Collaboration | Minimum                
Disaggregation of Revenue [Line Items]                
Royalty percent on net sales (as a percent)       4.00%        
GSK | GlaxoSmithKline Collaboration | Maximum                
Disaggregation of Revenue [Line Items]                
Royalty percent on net sales (as a percent)       8.00%        
GSK | Royalties                
Disaggregation of Revenue [Line Items]                
Collaboration revenue         22,200,000 11,000,000 40,400,000 18,200,000
GSK | Royalty Agreement, Up To $1.0 billion | PD-1 (Jemperli/Dostarlimab)                
Disaggregation of Revenue [Line Items]                
Royalty percent on net sales (as a percent)     8.00%          
Net sales royalty     $ 1,000,000,000          
GSK | Royalty Agreement, Above $1. 0 billion Below $1.5 Billion | PD-1 (Jemperli/Dostarlimab)                
Disaggregation of Revenue [Line Items]                
Royalty percent on net sales (as a percent)     12.00%          
GSK | Royalty Agreement, Above $1. 0 billion Below $1.5 Billion | Minimum | PD-1 (Jemperli/Dostarlimab)                
Disaggregation of Revenue [Line Items]                
Net sales royalty     $ 1,000,000,000          
GSK | Royalty Agreement, Above $1. 0 billion Below $1.5 Billion | Maximum | PD-1 (Jemperli/Dostarlimab)                
Disaggregation of Revenue [Line Items]                
Net sales royalty     $ 1,500,000,000          
GSK | Royalty Agreement, Above $1. 5 billion Below $2.5 Billion | PD-1 (Jemperli/Dostarlimab)                
Disaggregation of Revenue [Line Items]                
Royalty percent on net sales (as a percent)     20.00%          
GSK | Royalty Agreement, Above $1. 5 billion Below $2.5 Billion | Minimum | PD-1 (Jemperli/Dostarlimab)                
Disaggregation of Revenue [Line Items]                
Net sales royalty     $ 1,500,000,000          
GSK | Royalty Agreement, Above $1. 5 billion Below $2.5 Billion | Maximum | PD-1 (Jemperli/Dostarlimab)                
Disaggregation of Revenue [Line Items]                
Net sales royalty     $ 2,500,000,000          
GSK | Royalty Agreement, Above $2.5 billion | PD-1 (Jemperli/Dostarlimab)                
Disaggregation of Revenue [Line Items]                
Royalty percent on net sales (as a percent)     25.00%          
Net sales royalty     $ 2,500,000,000          
GSK | Jemperli Royalty Monetization Agreement                
Disaggregation of Revenue [Line Items]                
Collaboration revenue         21,100,000 10,100,000 38,400,000 16,300,000
GSK | Zejula Royalty Monetization Agreement                
Disaggregation of Revenue [Line Items]                
Collaboration revenue         1,100,000 900,000 2,000,000 1,900,000
GSK | Zejula revenue prior to the Zejula Royalty Monetization Agreement                
Disaggregation of Revenue [Line Items]                
Collaboration revenue           $ 900,000   $ 1,900,000
Vanda | Exclusive License Agreement                
Disaggregation of Revenue [Line Items]                
Royalty percent on net sales (as a percent) 10.00%              
Upfront payment $ 15,000,000              
Other income (expense), net         3,500,000   5,400,000  
Transaction costs expensed         2,500,000   2,500,000  
Vanda | Exclusive License Agreement | License                
Disaggregation of Revenue [Line Items]                
Collaboration revenue         0   9,600,000  
Upfront payment 10,000,000              
Vanda | Exclusive License Agreement | Transition services revenue                
Disaggregation of Revenue [Line Items]                
Collaboration revenue         100,000   100,000  
Vanda | Exclusive License Agreement | Existing drug supply                
Disaggregation of Revenue [Line Items]                
Upfront payment $ 5,000,000              
Centessa Pharmaceuticals (UK) Limited (Centessa) | GlaxoSmithKline Collaboration                
Disaggregation of Revenue [Line Items]                
Potential future payments   $ 10,000,000     $ 10,000,000   $ 10,000,000  
Centessa Pharmaceuticals (UK) Limited (Centessa) | GlaxoSmithKline Collaboration | License Agreement, Centessa Pharmaceuticals (UK) Limited                
Disaggregation of Revenue [Line Items]                
Cash payment   4,000,000            
Transaction costs incurred   300,000            
Reimbursement   3,000,000            
Total transferred   $ 7,300,000